Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04172766 · ClinicalTrials.gov registry record
Apple Hearing Study
A clinical trial of Hearing Loss and Tinnitus, sponsored by Apple.
- Active
- Registry status
- 300,000
- Enrollment target
- 1
- Study location
NCT04172766: Active study of Hearing Loss and Tinnitus, sponsored by Apple.
NCT04172766 is a study of Hearing Loss and Tinnitus that is active but no longer recruiting, run by Apple. The registered enrollment target is 300,000 participants, above the 949-participant average among 58 other Hearing Loss trials with a reported enrollment target (31512% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04172766, a study of Hearing Loss and Tinnitus, is active but no longer recruiting, sponsored by Apple.
- ACTIVE NOT RECRUITING
- Registry status
- 300,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The Apple Hearing Study is a partnership between the University of Michigan and Apple to study sound exposure and its impact on hearing health. This groundbreaking study will advance the understanding of how hearing could be impacted over time by exposure to sound at certain levels. The investigators will measure headphone and environmental sound exposures over time among participants, and determine how these exposures impact hearing and stress levels. US residents who own an iPhone, download the Apple Research app and consent to participate will be randomly assigned to two groups, one with a "Basic" user interface in the Research app, and one with an "Advanced" user interface. Users in the "Advanced" group will receive additional information about their exposures and be given additional surveys and hearing tests based on their music and environmental sound exposures. The study will provide investigators with a better understanding of listening behavior and its overall impact on hearing health. This information will in turn help guide public health policy and prevention programs designed to protect and promote hearing health in the US and globally.
Primary Outcome
For the entire cohort over various timeframes
Conditions Studied
Study Locations (1)
Michigan
- University of Michigan School of Public Health - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300,000 participants |
| Start Date | 2019-11-14 |
| Est. Completion | 2029-12 |
What the registry record for NCT04172766 still lists
NCT04172766 is an observational study that tracks outcomes without assigning an intervention. Its 300,000 participants enrollment target places it among the larger protocols in the corpus, above the 949-participant average among 58 other Hearing Loss trials with a reported enrollment target (31512% higher).
The record links to 3 conditions, with Hearing Loss appearing as the primary indexed condition, and to 0 interventions.
NCT04172766 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT04172766 about?
NCT04172766 is a clinical study titled "Apple Hearing Study". The Apple Hearing Study is a partnership between the University of Michigan and Apple to study sound exposure and its impact on hearing health. This groundbreaking study will advance the understanding of how hearing could be impacted over time by exposure to sound at certain levels. The investigator...
What is the current status of trial NCT04172766?
This trial is currently active not recruiting. The enrollment target is 300,000 participants. The study started on 2019-11-14. Estimated completion is 2029-12.
What conditions does trial NCT04172766 study?
This clinical trial studies the following conditions: Hearing Loss, Tinnitus, Hearing Loss, Noise-Induced.
Who is sponsoring clinical trial NCT04172766?
This trial is sponsored by Apple, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04172766 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hearing Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04172766's enrollment target sits among peer trials
300,000 1st of 58 higher than 58 of 58 other Hearing Loss trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hearing Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Access and Affordability of Adult Hearing Healthcare
RECRUITING · NA
-
AI Noise Reduction in Phonak Hearing Aids
RECRUITING · NA
-
Investigation of a Device to Deliver Intra-Operative Therapeutic Hypothermia for Hearing Preservation in Cochlear Implantation
RECRUITING · NA
-
Auditory-Cognitive Training to Optimize Outcomes for Older CI Users
RECRUITING · NA
-
Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
RECRUITING · Phase 1
-
NIDCD Otolaryngology Clinical Protocol Biospecimen Bank
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02280733 · 300,000 participants
A Real-World Registry of Chronic Wounds and Ulcers
- NCT06694181 · 300,000 participants
Safe and Explainable AI
- NCT07314697 · 300,000 participants · NA
Arrival Time Implementation
- NCT05365048 · 301,201 participants · NA
Provider Recommendation and HPV Vaccination
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI